N
GSK icon

Natixis’s GSK GSK Stock Holding History

Natixis’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-4,181
Closed -$228K – 1235
2022
Q1 		$228K Buy
+4,181
New +$227K ﹤0.01% 1097
2020
Q3 		– Sell
-9,432
Closed -$481K – 812
2020
Q2 		$481K Buy
+9,432
New +$484K ﹤0.01% 623
2020
Q1 		– Sell
-15,390
Closed -$906K – 769
2019
Q4 		$906K Buy
15,390
+6,720
+78% +$374K 0.01% 658
2019
Q3 		$463K Buy
8,670
+1,713
+25% +$88.1K ﹤0.01% 690
2019
Q2 		$348K Sell
6,957
-13,207
-65% -$663K ﹤0.01% 645
2019
Q1 		$1.05M Buy
20,164
+3,398
+20% +$170K 0.01% 581
2018
Q4 		$801K Sell
16,766
-5,285
-24% -$260K 0.01% 544
2018
Q3 		$1.11M Buy
22,051
+4,514
+26% +$229K 0.01% 558
2018
Q2 		$884K Buy
17,537
+2,991
+21% +$151K ﹤0.01% 627
2018
Q1 		$701K Sell
14,546
-43,120
-75% -$2.01M ﹤0.01% 635
2017
Q4 		$2.56M Buy
57,666
+51,096
+778% +$2.36M 0.02% 382
2017
Q3 		$333K Buy
+6,570
New +$333K ﹤0.01% 856
2016
Q3 		– Sell
-5,825
Closed -$316K – 544
2016
Q2 		$316K Buy
+5,825
New +$307K 0.01% 361
2015
Q4 		– Sell
-10,697
Closed -$514K – 337
2015
Q3 		$514K Sell
10,697
-310
-3% -$16.1K 0.01% 194
2015
Q2 		$573K Buy
11,007
+662
+6% +$37.3K 0.01% 244
2015
Q1 		$597K Buy
10,345
+2,067
+25% +$118K 0.01% 287
2014
Q4 		$442K Sell
8,278
-408
-5% -$22.8K 0.01% 294
2014
Q3 		$499K Buy
8,686
+4,752
+121% +$291K 0.01% 304
2014
Q2 		$263K Buy
+3,934
New +$266K ﹤0.01% 413

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Parallax Volatility Advisers
Parallax Volatility Advisers San Francisco, California $38.6B AUM 45.89% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Natixis's GSK Position: Q2 2022 in Review

Natixis sold out of GSK (GSK) in Q2 2022, closing a stake of 4,181 shares — an estimated $228K sold.

Natixis first reported a position in GSK in Q2 2014 and held it in 19 quarters. The position peaked at $2.56M in Q4 2017. 900 funds tracked by Wall St. Rank hold GSK as of Q2 2022.

  • Natixis reported no remaining GSK position as of Q2 2022 after selling out during the quarter.
  • Natixis sold 4,181 GSK shares in Q2 2022, an estimated $228K.
  • Natixis first reported a position in GSK in Q2 2014 and held it in 19 quarters.
  • Natixis's GSK position peaked at $2.56M in Q4 2017.
  • 900 funds tracked by Wall St. Rank held GSK as of Q2 2022.

Based on Natixis's 13F filing for Q2 2022, filed 12 Aug 2022.